^
Association details:
| Biomarker: | EGFR exon 19 mutation |
|---|---|
| Cancer: | Pancreatic Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma
Published date:
02/17/2021
Excerpt:
...we present the case of a patient with metastatic PDAC with progression on two lines of combination chemotherapy whose tumor was found to harbor an activating exon 19 EGFR mutation and wild type KRAS and experienced durable tumor response beyond 42 weeks on erlotinib.
DOI:
10.1016/j.ctarc.2021.100342
